Actively Recruiting
Evaluating Safety, Efficacy, and Cellular Kinetics of CT0596 CAR-T Therapy in Patients With RelapsedRefractory Multiple Myeloma
Led by UCARsgen Biotech Limited · Updated on 2026-09-17
68
Participants Needed
2
Research Sites
17 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating CT0596, a chimeric antigen receptor T-cell CAR-T therapy, in patients with relapsed or refractory multiple myeloma RR MM who have already undergone multiple prior treatments. This Phase III, single-arm, open-label, multicenter clinical trial aims to study the safety, tolerability, effectiveness, how the cells behave in the body, and immune responses to CT0596 in these patients. The study uses a dose-escalation method in Phase I to find the best dose, then confirms the treatments effects in Phase II. Participants receive CT0596 CAR-T cells, with Phase I focusing on finding the maximum tolerated or recommended dose through a careful increase in dosage. Phase II evaluates the confirmed effective dose by measuring overall response rates at 12 weeks after infusion, using established response criteria. The study tracks outcomes over time up to 24 months, including safety events, response rates, disease progression, survival, and biological markers related to the therapy. During the trial, participants undergo multiple clinical visits for infusion and monitoring. Researchers assess side effects, treatment responses, blood markers, immune reactions, and disease status regularly up to two years after treatment. The trial includes evaluations by independent reviewers to confirm responses. Overall, participants are closely monitored for safety and treatment effects throughout the study period, which lasts until the study completion in 2031.
CONDITIONS
Brief Title
A Clinical Study of CT0596 CAR-T in Relapsed/Refractory Multiple Myeloma
Research Team
J
Juan Du
C
Chengcheng Fu
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here